Business UpdateMay 28, 2026, 04:03 PM
Emergent BioSolutions Secures $64.5M Contract for Botulism Antitoxin
AI Summary
Emergent BioSolutions Inc. announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the U.S. Department of Health and Human Services (HHS). This modification to an existing 10-year contract ensures the continued supply of BAT® (Botulism Antitoxin Heptavalent), an antitoxin used for treating symptomatic botulism. The company highlighted its ongoing support for U.S. biodefense and preparedness priorities, leveraging its specialized capabilities and North American supply chain.
Key Highlights
- Emergent BioSolutions secured a contract modification valued at approximately $64.5 million.
- The contract was awarded by the Administration for Strategic Preparedness and Response (ASPR), a division of HHS.
- The modification is for the supply of BAT® (Botulism Antitoxin Heptavalent).
- This builds on an existing 10-year contract (75A50119C00075) with ASPR.
- BAT® is indicated for treating symptomatic botulism in adults and pediatric patients.
- Emergent leverages its North American supply chain for critical medical countermeasures.
Price Impact
More from EBS